Neumora Therapeutics Reports Full-Year 2025 Results, Secures New Financing, and Provides Key Pipeline Updates Amidst Legal Challenge

summarizeSummary

Neumora Therapeutics reported a net loss of $236.9 million for full-year 2025, with cash and equivalents of $182.5 million, projecting a runway of at least 12 months after securing $60.0 million in new debt and $19.7 million from an ATM offering, while facing a securities class action lawsuit and having repriced stock options.

check_boxKey Events

• Full-Year 2025 Financials

  Neumora Therapeutics reported a net loss of $236.9 million for full-year 2025, a slight improvement from $243.8 million in 2024. Cash and cash equivalents stood at $182.5 million as of December 31, 2025, with management projecting a liquidity runway of at least 12 months.

• New Financing Secured

  The company drew $60.0 million from a $125.0 million term loan facility with K2 HealthVentures LLC and received $19.7 million in net proceeds from an At-The-Market (ATM) equity offering during 2025. The term loan includes an option for K2HV to convert up to $12.5 million of principal into common stock, of which $4.0 million was converted by December 2025.

• Key Pipeline Updates and Setbacks

  Topline data for the Phase 3 KOASTAL-2 and -3 studies of navacaprant (MDD) are expected in Q2 2026. The Phase 1 trial for NMRA-215 (obesity) has been delayed to Q1 2027 due to unexpected adverse findings in a 13-week rat toxicology study, which the company believes may be related to a study conduct issue.

• Stock Option Repricing

  The Board of Directors approved an option repricing in February 2025 (shareholder approved May 2025), lowering the exercise price of outstanding stock options to $0.72 per share. This resulted in $4.2 million of incremental stock compensation expense, with $1.5 million recognized in 2025.

auto_awesomeAnalysis

Neumora Therapeutics' annual report reveals a complex financial and operational landscape. While the company reported a slight reduction in net loss for 2025, its cash burn from operations increased, necessitating significant new financing. The $60.0 million drawn from a term loan and $19.7 million from an At-The-Market (ATM) offering in 2025 were crucial for extending its cash runway to at least 12 months. However, these financing activities, particularly the term loan with its conversion option, introduce potential dilution. The upcoming Phase 3 data for navacaprant in Q2 2026 is a critical binary event, especially following the prior KOASTAL-1 study failure. Further, the delay of the NMRA-215 Phase 1 trial due to unexpected toxicology findings adds a setback to the pipeline. The board's decision to reprice stock options to a lower strike price in May 2025, coupled with an ongoing securities class action lawsuit related to its IPO, signals significant challenges and potential governance concerns that could impact investor confidence.